共 50 条
Comparative Review of the Carbapenems
被引:0
|作者:
George G. Zhanel
Ryan Wiebe
Leanne Dilay
Kristjan Thomson
Ethan Rubinstein
Daryl J. Hoban
Ayman M. Noreddin
James A. Karlowsky
机构:
[1] University of Manitoba,Department of Medical Microbiology, Faculty of Medicine
[2] University of Manitoba,Department of Medicine
[3] Health Sciences Center,Department of Clinical Microbiology
[4] University of Minnesota,College of Pharmacy
[5] Health Sciences Centre,MS 673 Microbiology
来源:
Drugs
|
2007年
/
67卷
关键词:
Imipenem;
Meropenem;
Cefepime;
Nosocomial Pneumonia;
Ertapenem;
D O I:
暂无
中图分类号:
学科分类号:
摘要:
The carbapenems are β-lactam antimicrobial agents with an exceptionally broad spectrum of activity. Older carbapenems, such as imipenem, were often susceptible to degradation by the enzyme dehydropeptidase-1 (DHP-1) located in renal tubules and required co-administration with a DHP-1 inhibitor such as cilastatin. Later additions to the class such as meropenem, ertapenem and doripenem demonstrated increased stability to DHP-1 and are administered without a DHP-1 inhibitor. Like all β-lactam antimicrobial agents, carbapenems act by inhibiting bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs). Carbapenems are stable to most β-lactamases including AmpC β-lactamases and extended-spectrum β-lactamases. Resistance to carbapenems develops when bacteria acquire or develop structural changes within their PBPs, when they acquire metallo-β-lactamases that are capable of rapidly degrading carbapenems, or when changes in membrane permeability arise as a result of loss of specific outer membrane porins.
引用
收藏
页码:1027 / 1052
页数:25
相关论文